Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Background. Chronic kidney disease (CKD) has become a global public health problem with a high prevalence and mortality. There is no sensitive and effective markers for chronic kidney disease. Previous studies proposed suPAR as an early predict biomarker for chronic kidney disease, but the results a...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2019, Vol.2019 (2019), p.1-9 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | 2019 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2019 |
| creator | Zhu, Lei Yang, Ke-hu Liu, Jian Huang, Qiangru Shuai, Tiankui Yan, Peijing Xiong, Huaiyu |
| description | Background. Chronic kidney disease (CKD) has become a global public health problem with a high prevalence and mortality. There is no sensitive and effective markers for chronic kidney disease. Previous studies proposed suPAR as an early predict biomarker for chronic kidney disease, but the results are controversial. Therefore, the purpose of the current meta-analysis is to evaluate the association between suPAR and CKD. Methods. We searched the PubMed, Embase, Cochrane Library databases, and Web of Science before May 1, 2019. The search was based on the key words including suPAR and CKD. Data are extracted independently according to standard format, and quality analysis is performed. We extracted the concentration of suPAR and hazard rate (HR) values of mortality, cardiovascular disease, and end-stage renal disease. Results. There were 14 studies fulfilling the criteria. The concentration of suPAR was higher in patients with CKD than that in the control group (P |
| doi_str_mv | 10.1155/2019/6927456 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6899318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A614683257</galeid><sourcerecordid>A614683257</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-5af0c2f64bd5487f22ae7ca83a954cbe80cc839b3acecf6ec652542970f971d43</originalsourceid><addsrcrecordid>eNqNkV1v0zAUhiMEYtPYHdfIEpcQFn8m5gIpKp-iCMS2a8txTlqPxO7stFX-xn7xXFo6uMM3tuTH7zk-T5Y9x8UbjDm_IAWWF0KSknHxKDslFLNcYIYfH8-UnmTnMd4UaVVYFFI8zU4oripBGDnN7uoYvbF6tN6hBsYtgEOXvl83PaDr4H9ZpyPkV9MK0I9ex8E6v0hIbUa70aMP6CcYWO0Oc9hAH5F2LZotg3fWoK-2dTCh9zZCSnmLanQ5xRGGVM6khxsL29_8Nxh1XjvdT9HGZ9mTTvcRzg_7WXb98cPV7HM-__7py6ye54YJMeZcd4UhnWBNy1lVdoRoKI2uqJacmQaqwpiKyoZqA6YTYAQnnBFZFp0sccvoWfZun7taNwO0BtwYdK9WwQ46TMprq_69cXapFn6jRCVlmmAKeHkICP52DXFUN34d0i-iIpQQQXga-QO10D0o6zqfwsxgo1F1UiUqSniZqNd7ygQfY4Du2Acu1E612qlWB9UJf_F370f4j9gEvNoDS-tavbX_GZfUpNr6gcakLDCh90wFvK0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2322625008</pqid></control><display><type>article</type><title>Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhu, Lei ; Yang, Ke-hu ; Liu, Jian ; Huang, Qiangru ; Shuai, Tiankui ; Yan, Peijing ; Xiong, Huaiyu</creator><contributor>Nihalani, Deepak ; Deepak Nihalani</contributor><creatorcontrib>Zhu, Lei ; Yang, Ke-hu ; Liu, Jian ; Huang, Qiangru ; Shuai, Tiankui ; Yan, Peijing ; Xiong, Huaiyu ; Nihalani, Deepak ; Deepak Nihalani</creatorcontrib><description>Background. Chronic kidney disease (CKD) has become a global public health problem with a high prevalence and mortality. There is no sensitive and effective markers for chronic kidney disease. Previous studies proposed suPAR as an early predict biomarker for chronic kidney disease, but the results are controversial. Therefore, the purpose of the current meta-analysis is to evaluate the association between suPAR and CKD. Methods. We searched the PubMed, Embase, Cochrane Library databases, and Web of Science before May 1, 2019. The search was based on the key words including suPAR and CKD. Data are extracted independently according to standard format, and quality analysis is performed. We extracted the concentration of suPAR and hazard rate (HR) values of mortality, cardiovascular disease, and end-stage renal disease. Results. There were 14 studies fulfilling the criteria. The concentration of suPAR was higher in patients with CKD than that in the control group (P<0.001; SMD: −2.17; 95% CI: −2.71, −1.63; I2 = 67.4%). SuPAR had a higher risk of mortality (P=0.001; HR: 1.72; 95% CI: 1.24, 2.39; I2 = 68.0%). The higher suPAR level increased the risk of cardiovascular disease (P<0.001; HR: 3.06; 95% CI: 2.21, 4.22; I2 = 0.0%) and the risk of end-stage renal disease (P<0.001; HR: 1.40; 95% CI: 1.22, 1.60; I2 = 0.0%). Conclusions. Monitoring suPAR concentrations may be used for early diagnosis and prognosis for patients with CKD, and the higher suPAR increased the risk of mortality, cardiovascular events, and end-stage renal disease.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2019/6927456</identifier><identifier>PMID: 31886242</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Analysis ; Atherosclerosis ; Biomarkers ; Biomarkers - blood ; Cardiology ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - complications ; Cause of Death ; Chronic kidney failure ; Databases, Factual ; Diabetes ; End-stage renal disease ; Health aspects ; Health risks ; Humans ; Kidney diseases ; Kidney Failure, Chronic ; Kidneys ; Medical research ; Medicine ; Medicine, Experimental ; Meta-analysis ; Mortality ; Nephrology ; Prognosis ; Public health ; Quality ; Receptors, Urokinase Plasminogen Activator - blood ; Renal Insufficiency, Chronic - blood ; Renal Insufficiency, Chronic - complications ; Renal Insufficiency, Chronic - diagnosis ; Review ; Risk ; Risk Factors ; Studies ; Systematic review ; U-Plasminogen activator ; Urokinase</subject><ispartof>BioMed research international, 2019, Vol.2019 (2019), p.1-9</ispartof><rights>Copyright © 2019 Tiankui Shuai et al.</rights><rights>COPYRIGHT 2019 John Wiley & Sons, Inc.</rights><rights>Copyright © 2019 Tiankui Shuai et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2019 Tiankui Shuai et al. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-5af0c2f64bd5487f22ae7ca83a954cbe80cc839b3acecf6ec652542970f971d43</citedby><cites>FETCH-LOGICAL-c466t-5af0c2f64bd5487f22ae7ca83a954cbe80cc839b3acecf6ec652542970f971d43</cites><orcidid>0000-0001-7864-3012 ; 0000-0002-1825-571X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899318/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899318/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4022,27921,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31886242$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Nihalani, Deepak</contributor><contributor>Deepak Nihalani</contributor><creatorcontrib>Zhu, Lei</creatorcontrib><creatorcontrib>Yang, Ke-hu</creatorcontrib><creatorcontrib>Liu, Jian</creatorcontrib><creatorcontrib>Huang, Qiangru</creatorcontrib><creatorcontrib>Shuai, Tiankui</creatorcontrib><creatorcontrib>Yan, Peijing</creatorcontrib><creatorcontrib>Xiong, Huaiyu</creatorcontrib><title>Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Background. Chronic kidney disease (CKD) has become a global public health problem with a high prevalence and mortality. There is no sensitive and effective markers for chronic kidney disease. Previous studies proposed suPAR as an early predict biomarker for chronic kidney disease, but the results are controversial. Therefore, the purpose of the current meta-analysis is to evaluate the association between suPAR and CKD. Methods. We searched the PubMed, Embase, Cochrane Library databases, and Web of Science before May 1, 2019. The search was based on the key words including suPAR and CKD. Data are extracted independently according to standard format, and quality analysis is performed. We extracted the concentration of suPAR and hazard rate (HR) values of mortality, cardiovascular disease, and end-stage renal disease. Results. There were 14 studies fulfilling the criteria. The concentration of suPAR was higher in patients with CKD than that in the control group (P<0.001; SMD: −2.17; 95% CI: −2.71, −1.63; I2 = 67.4%). SuPAR had a higher risk of mortality (P=0.001; HR: 1.72; 95% CI: 1.24, 2.39; I2 = 68.0%). The higher suPAR level increased the risk of cardiovascular disease (P<0.001; HR: 3.06; 95% CI: 2.21, 4.22; I2 = 0.0%) and the risk of end-stage renal disease (P<0.001; HR: 1.40; 95% CI: 1.22, 1.60; I2 = 0.0%). Conclusions. Monitoring suPAR concentrations may be used for early diagnosis and prognosis for patients with CKD, and the higher suPAR increased the risk of mortality, cardiovascular events, and end-stage renal disease.</description><subject>Analysis</subject><subject>Atherosclerosis</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cause of Death</subject><subject>Chronic kidney failure</subject><subject>Databases, Factual</subject><subject>Diabetes</subject><subject>End-stage renal disease</subject><subject>Health aspects</subject><subject>Health risks</subject><subject>Humans</subject><subject>Kidney diseases</subject><subject>Kidney Failure, Chronic</subject><subject>Kidneys</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine, Experimental</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>Nephrology</subject><subject>Prognosis</subject><subject>Public health</subject><subject>Quality</subject><subject>Receptors, Urokinase Plasminogen Activator - blood</subject><subject>Renal Insufficiency, Chronic - blood</subject><subject>Renal Insufficiency, Chronic - complications</subject><subject>Renal Insufficiency, Chronic - diagnosis</subject><subject>Review</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>Studies</subject><subject>Systematic review</subject><subject>U-Plasminogen activator</subject><subject>Urokinase</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkV1v0zAUhiMEYtPYHdfIEpcQFn8m5gIpKp-iCMS2a8txTlqPxO7stFX-xn7xXFo6uMM3tuTH7zk-T5Y9x8UbjDm_IAWWF0KSknHxKDslFLNcYIYfH8-UnmTnMd4UaVVYFFI8zU4oripBGDnN7uoYvbF6tN6hBsYtgEOXvl83PaDr4H9ZpyPkV9MK0I9ex8E6v0hIbUa70aMP6CcYWO0Oc9hAH5F2LZotg3fWoK-2dTCh9zZCSnmLanQ5xRGGVM6khxsL29_8Nxh1XjvdT9HGZ9mTTvcRzg_7WXb98cPV7HM-__7py6ye54YJMeZcd4UhnWBNy1lVdoRoKI2uqJacmQaqwpiKyoZqA6YTYAQnnBFZFp0sccvoWfZun7taNwO0BtwYdK9WwQ46TMprq_69cXapFn6jRCVlmmAKeHkICP52DXFUN34d0i-iIpQQQXga-QO10D0o6zqfwsxgo1F1UiUqSniZqNd7ygQfY4Du2Acu1E612qlWB9UJf_F370f4j9gEvNoDS-tavbX_GZfUpNr6gcakLDCh90wFvK0</recordid><startdate>2019</startdate><enddate>2019</enddate><creator>Zhu, Lei</creator><creator>Yang, Ke-hu</creator><creator>Liu, Jian</creator><creator>Huang, Qiangru</creator><creator>Shuai, Tiankui</creator><creator>Yan, Peijing</creator><creator>Xiong, Huaiyu</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7864-3012</orcidid><orcidid>https://orcid.org/0000-0002-1825-571X</orcidid></search><sort><creationdate>2019</creationdate><title>Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis</title><author>Zhu, Lei ; Yang, Ke-hu ; Liu, Jian ; Huang, Qiangru ; Shuai, Tiankui ; Yan, Peijing ; Xiong, Huaiyu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-5af0c2f64bd5487f22ae7ca83a954cbe80cc839b3acecf6ec652542970f971d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Analysis</topic><topic>Atherosclerosis</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cause of Death</topic><topic>Chronic kidney failure</topic><topic>Databases, Factual</topic><topic>Diabetes</topic><topic>End-stage renal disease</topic><topic>Health aspects</topic><topic>Health risks</topic><topic>Humans</topic><topic>Kidney diseases</topic><topic>Kidney Failure, Chronic</topic><topic>Kidneys</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine, Experimental</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>Nephrology</topic><topic>Prognosis</topic><topic>Public health</topic><topic>Quality</topic><topic>Receptors, Urokinase Plasminogen Activator - blood</topic><topic>Renal Insufficiency, Chronic - blood</topic><topic>Renal Insufficiency, Chronic - complications</topic><topic>Renal Insufficiency, Chronic - diagnosis</topic><topic>Review</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>Studies</topic><topic>Systematic review</topic><topic>U-Plasminogen activator</topic><topic>Urokinase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Lei</creatorcontrib><creatorcontrib>Yang, Ke-hu</creatorcontrib><creatorcontrib>Liu, Jian</creatorcontrib><creatorcontrib>Huang, Qiangru</creatorcontrib><creatorcontrib>Shuai, Tiankui</creatorcontrib><creatorcontrib>Yan, Peijing</creatorcontrib><creatorcontrib>Xiong, Huaiyu</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Lei</au><au>Yang, Ke-hu</au><au>Liu, Jian</au><au>Huang, Qiangru</au><au>Shuai, Tiankui</au><au>Yan, Peijing</au><au>Xiong, Huaiyu</au><au>Nihalani, Deepak</au><au>Deepak Nihalani</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2019</date><risdate>2019</risdate><volume>2019</volume><issue>2019</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Background. Chronic kidney disease (CKD) has become a global public health problem with a high prevalence and mortality. There is no sensitive and effective markers for chronic kidney disease. Previous studies proposed suPAR as an early predict biomarker for chronic kidney disease, but the results are controversial. Therefore, the purpose of the current meta-analysis is to evaluate the association between suPAR and CKD. Methods. We searched the PubMed, Embase, Cochrane Library databases, and Web of Science before May 1, 2019. The search was based on the key words including suPAR and CKD. Data are extracted independently according to standard format, and quality analysis is performed. We extracted the concentration of suPAR and hazard rate (HR) values of mortality, cardiovascular disease, and end-stage renal disease. Results. There were 14 studies fulfilling the criteria. The concentration of suPAR was higher in patients with CKD than that in the control group (P<0.001; SMD: −2.17; 95% CI: −2.71, −1.63; I2 = 67.4%). SuPAR had a higher risk of mortality (P=0.001; HR: 1.72; 95% CI: 1.24, 2.39; I2 = 68.0%). The higher suPAR level increased the risk of cardiovascular disease (P<0.001; HR: 3.06; 95% CI: 2.21, 4.22; I2 = 0.0%) and the risk of end-stage renal disease (P<0.001; HR: 1.40; 95% CI: 1.22, 1.60; I2 = 0.0%). Conclusions. Monitoring suPAR concentrations may be used for early diagnosis and prognosis for patients with CKD, and the higher suPAR increased the risk of mortality, cardiovascular events, and end-stage renal disease.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>31886242</pmid><doi>10.1155/2019/6927456</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7864-3012</orcidid><orcidid>https://orcid.org/0000-0002-1825-571X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2019, Vol.2019 (2019), p.1-9 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6899318 |
| source | MEDLINE; PubMed Central Open Access; Wiley-Blackwell Open Access Titles; PubMed Central; Alma/SFX Local Collection |
| subjects | Analysis Atherosclerosis Biomarkers Biomarkers - blood Cardiology Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - blood Cardiovascular Diseases - complications Cause of Death Chronic kidney failure Databases, Factual Diabetes End-stage renal disease Health aspects Health risks Humans Kidney diseases Kidney Failure, Chronic Kidneys Medical research Medicine Medicine, Experimental Meta-analysis Mortality Nephrology Prognosis Public health Quality Receptors, Urokinase Plasminogen Activator - blood Renal Insufficiency, Chronic - blood Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - diagnosis Review Risk Risk Factors Studies Systematic review U-Plasminogen activator Urokinase |
| title | Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T20%3A30%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20Soluble%20Urokinase-Type%20Plasminogen%20Activator%20Receptor%20Levels%20and%20Chronic%20Kidney%20Disease:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=BioMed%20research%20international&rft.au=Zhu,%20Lei&rft.date=2019&rft.volume=2019&rft.issue=2019&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2019/6927456&rft_dat=%3Cgale_pubme%3EA614683257%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2322625008&rft_id=info:pmid/31886242&rft_galeid=A614683257&rfr_iscdi=true |